文章目录

Gustave Roussy的研究结果

原文发布日期：2020-09-22

英文摘要：

摘要翻译：

原文链接：

文章：

Gustave Roussy的研究结果

results from the Gustave Roussy cohort

原文发布日期：2020-09-22

英文摘要：

Patients with cancer are presumed to be at increased risk of severe COVID-19 outcomes due to underlying malignancy and treatment-induced immunosuppression. Of the first 178 patients managed for COVID-19 at the Gustave Roussy Cancer Centre, 125 (70.2%) were hospitalized, 47 (26.4%) developed clinical worsening and 31 (17.4%) died. An age of over 70 years, smoking status, metastatic disease, cytotoxic chemotherapy and an Eastern Cooperative Oncology Group score of ≥2 at the last visit were the strongest determinants of increased risk of death. In multivariable analysis, the Eastern Cooperative Oncology Group score remained the only predictor of death. In contrast, immunotherapy, hormone therapy and targeted therapy did not increase clinical worsening or death risk. Biomarker studies found that C-reactive protein and lactate dehydrogenase levels were significantly associated with an increased risk of clinical worsening, while C-reactive protein and D-dimer levels were associated with an increased risk of death. COVID-19 management impacted the oncological treatment strategy, inducing a median 20 d delay in 41% of patients and adaptation of the therapeutic strategy in 30% of patients.

摘要翻译：

患有癌症的患者被认为更容易出现严重COVID-19后果，这主要是由于原发恶性肿瘤以及因免疫抑制而引起的接受治疗的影响。格速菲·鲁索癌症中心管理的178名COVID-19患者中，有125人住院，47人病情恶化，31人去世。年龄超过70岁、吸烟史、转移性疾病、化疗药物使用和最后检查时ECOG得分≥2是死亡风险最高的重要因素。在多重分析中，只有ECOG分值是死亡的预测因素。免疫治疗、激素治疗和靶向治疗没有增加病情恶化或死亡的风险。生物标志物研究发现，CRP和乳酸脱氢酶水平与病情恶化的风险显著相关，而CRP和D-dimer水平则与死亡风险相关。管理COVID-19会影响癌症治疗策略，导致41%患者出现20天的延迟，并且调整治疗策略在30%的患者中实施。